#5 - Apellis Pharmaceuticals (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a mid-cap company that is flying under the radar of many investors in this space. Apellis focuses on C3, the central protein of the complement cascade. The complement cascade is the part of the body’s immune system that fights off infection. When this is overactivated, it can attach and destroy healthy cells which can lead to a number of diseases.
In July 2021, Apellis announced a collaboration with Beam Therapeutics to leverage that company’s base editing technology in an effort to develop new precision therapies for the eye, liver, and brain.
However, Apellis has a robust stand-alone pipeline including several that are in late-stage trials. It has to be stated that the company is still not profitable and is not likely to be anytime soon. But Apellis does enjoy significant institutional ownership of over 80% and is currently trading 30% below its consensus price target of over $70 per share.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Read More - Current Price
- $29.43
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 13 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $49.94 (69.7% Upside)
